Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation

Blood

Volumn 110, Issue 13, 2007, Pages 4234-4242

  Meeks, Shannon L ^a   Healey, John F ^a   Parker, Ernest T ^a   Barrow, Rachel T ^a   Lollar, Pete ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Emory Children's Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY; THROMBIN; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8A; F8 PROTEIN, HUMAN; PHOSPHOLIPID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HEMOPHILIA A; MEMBRANE BINDING; MOUSE; NONHUMAN; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; PROTEIN DOMAIN; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; FACTOR VIII; FACTOR VIIIA; HEMOPHILIA A; HUMANS; MICE; PHOSPHOLIPIDS; VON WILLEBRAND FACTOR;

EID: 39649102400     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-06-096842     Document Type: Article

References (45)

1. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, the Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A: safety, efficacy, and the development of inhibitors. N Engl J Med. 1993;328:453-459.
2. Bray GL, Gomperts ED, Courtier S, et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood. 1994;83:2428-2435.
3. Lusher JM, Lee CA, Kessler CM, Bedrosian CL, the Refacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia. 2003;9:38-49.
4. Kreuz W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost. 2002;28:285-290.
5. Lollar P, Parker CG. Subunit structure of thrombin-activated porcine factor VIII. Biochemistry. 1989;28:666-674.
6. Prescott R, Nakai H, Saenko EL, et al. The inhibitory antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with fVIII autoantibodies. Blood. 1997;89:3663-3671.
7. Arai M, Scandella D, Hoyer LW. Molecular basis of factor-VIII inhibition by human antibodies: antibodies that bind to the factor-VIII light chain prevent the interaction of factor-VIII with phospholipid. J Clin Invest. 1989;83:1978-1984.
8. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor binding to von Willebrand factor. J Biol Chem. 1994;269:11601-11605.
9. Nogami K, Shima M, Hosokawa K, et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem. 1999;274:31000-31007.
10. Nogami K, Shima M, Hosokawa K, et al. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. J Biol Chem. 2000;275:25774-25780.
11. Lajmanovich A, Hudry-Clergeon G, Freyssinet JM, Marguerie G. Human factor VIII procoagulant activity and phospholipid interactions. Biochim Biophys Acta. 1981;678:132-136.
12. Andersson LO, Brown JE. Interaction of factor VIII-von Willebrand factor with phospholipid vesicles. Biochem J. 1981;200:161-167.
13. Saenko EL, Scandella D. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. J Biol Chem. 1995;270:13826-13833.
14. Shima M, Scandella D, Yoshioka A, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost. 1993;69:240-246.
15. Shima M, Nakai H, Scandella D, et al. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor. Br J Haematol. 1995;91:714-721.
16. Jacquemin MG, Desqueper BG, Benhida A, et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood. 1998;92:496-506.
17. Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. J Biol Chem. 1997;272:18007-18014.
18. Saenko E, Sarafanov A, Greco N, et al. Use of surface plasmon resonance for studies of proteinprotein and protein-phospholipid membrane interactions: application to the binding of factor VIII to von Willebrand factor and to phosphatidylserine-containing membranes.[erratum appears in J Chromatogr A. 2000;872:323]. J Chromatogr A. 1999;852:59-71.
19. Scandella D, Gilbert GE, Shima M, et al. Some human inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248-2312 which overlap a phospholipid binding site. Blood. 1995;86:1811-1819.
20. Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem. 1996;271:27424-27431.
21. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem. 1988;263:10451-10455.
22. Hill-Eubanks DC, Parker CG, Lollar P. Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin. Proc Natl Acad Sci U S A. 1989;86:6508-6512.
23. Pratt KP, Shen BW, Takeshima K, et al. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature. 1999;402:439-442.
24. Spiegel PC Jr, Jacquemin M, Saint-Remy JM, Stoddard BL, Pratt KP. Structure of the factor VIII C2 domain-immunoglobulin G4κ Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood. 2001;98:13-19.
25. Barrow RT, Healey JF, Jacquemin MG, Saint-Remy JM, Lollar P. Antigenicity of putative phospholipid membrane binding residues in factor VIII. Blood. 2001;97:169-174.
26. Gilbert GE, Kaufman RJ, Arena AA, Miao H, Pipe SW. Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J Biol Chem. 2002;277:6374-6381.
27. Parker ET, Doering CB, Lollar P. A1 subunit-mediated regulation of thrombin-activated factor VIII A2 subunit dissociation. J Biol Chem. 2006;281:13922-13930.
28. Healey JF, Parker ET, Barrow RT, et al. The humoral response to human factor VIII in hemophilia A mice. J Thromb Haemost. 2007;5:512-517.
29. Bi L, Lawler AM, Antonarakis SE, et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10:119-121.
30. Kohler G, Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol. 1976;6:511-519.
31. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:869-872.
32. Barrow RT, Lollar P. Neutralization of anti-factor VIII inhibitors by recombinant porcine factor VIII. J Thromb Haemost. 2006;4:2223-2229.
33. Lollar P, Parker ET, Fay PJ. Coagulant properties of hybrid human/porcine factor VIII molecules. J Biol Chem. 1992;267:23652-23657.
34. Duffy EJ, Lollar P. Intrinsic pathway activation of factor X and its activation peptide-deficient derivative, factor X(Des 143-191). J Biol Chem. 1992;267:7821-7827.
35. Braden BC, Poljak RJ. Structural features of the reactions between antibodies and protein antigens. FASEB J. 1995;9:9-16.
36. Braden BC, Dall'Acqua W, Eisenstein E, et al. Protein motion and lock and key complementarity in antigen-antibody reactions. Pharmaceutica Acta Helvetiae. 1995;69:225-230.
37. Davies DR, Cohen GM. Interactions of protein antigens with antibodies. Proc Natl Acad Sci U S A. 1996;93:7-12.
38. Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood. 1982;60:1103-1109.
39. Lollar P, Parker CG. pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem. 1990;265:1688-1692.
40. Hill-Eubanks DC, Lollar P. von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain. J Biol Chem. 1990;265:17854-17858.
41. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII: correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry. 1986;25:505-512.
42. Davies DR, Padlan EA. Antibody-antigen complexes. Ann Rev Biochem. 1990;59:439-473.
43. Rock EP, Sibbald PR, Davis MM, Chien YH. CDR3 length in antigen-specific immune receptors. J Exp Med. 1994;179:323-328.
44. Lusher JM. Factor VIII inhibitors: etiology, characterization, natural history and management. Ann NY Acad Sci. 1987;509:89-102.
45. Parker ET, Healey JF, Barrow RT, Craddock HN, Lollar P. Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B cell epitope. Blood. 2004;104:704-710.